Any current/future new fundraising through debt or equity?

Promoter group plans a preferential equity infusion of INR 150 crore, expected before March 2026 or by Q1 FY27, subject to regulatory approvals. Around INR 200 crore equity expected from Morita towards their 20% stake in the JV by end of current quarter or Q1 FY27. Insurance claim recoveries of approximately INR 200 crore expected by March or April 2026. Overall, approximately INR 550 crore (equity + insurance) expected to come in this year or early next year. Debt discussions ongoing with banks to maintain a 70:30 debt-equity ratio for the JV capital; exact debt levels and repayments

Any current/future capex/capital investment/strategic investment?

Neogen Chemicals is progressing with the Pakhajan greenfield project, targeting: - Electrolyte commercial production in H1 FY27. - Electrolyte salts production in H2 FY27. - Equipment arrival and assembly underway; trial production expected soon. Rebuilding and expansion of the Dahej plant ongoing, with completion and commissioning expected by Q1 FY27 and capacity ramp-up by March 2026. Preferential equity infusion planned from Promoter Group of INR 150 crore by March 2026 to support growth and reduce interest burden. Joint venture with Morita Investment Ltd for LiPF6 salt production, wi

Future growth expectations in sales/revenue/volumes?

FY27 and FY28 are expected to see double-digit revenue growth in the base business, especially post the Dahej plant ramp-up. Battery chemicals segment projected to generate INR 400-500 crore revenue in FY27, considering limited salt sales from Pakhajan in H2 FY27. Electrolyte revenues are expected to increase in H2 FY27 due to capacity ramps by major customers like Ola, Exide, and Waaree. The Pakhajan salt plant’s full 30,000 MT capacity is targeted to be operational by end of H1 FY27, with gradual ramp-up based on business visibility. By end of 2027, India's battery cell manufacturing capacit

Future growth expectations in earnings/operating earnings/profits/EPS?

Neogen Chemicals expects steady revenue growth driven by the ramp-up of battery chemicals, including electrolyte and salts production at the Dahej and Pakhajan plants. FY27 battery chemicals revenue is guided at INR 400-500 crore with electrolyte production from Pakhajan starting in H1 FY27 and salts in H2. Base business (organic and inorganic chemicals) is expected to deliver double-digit revenue growth in FY27 and FY28, recovering from fire incident impacts. EBITDA impacted short-term by ramp-up costs, interim toll manufacturing, and higher interest expense related to Dahej plant reconstruct

Current/ Expected Orderbook/ Pending Orders?

Salt business has shown increased interest with many regular and non-regular customers. Majority of requirements for one key customer are complete, with final approval timelines expected by Q1 FY27. Three to four other customers have started sampling and approving, with audits planned between March and May 2026. Dahej site approval expected by June 2026; sales to start progressively from Q2 FY27 onwards. Pakhajan site target approval by September 2026, with trial production starting in H2 FY27 and sales from Q4 FY27. Significant inquiries for lithium salts and intermediates due to re

IN US

Sale is live|00:00:00left today

Neogen Chemicals LtdQ4 FY27Chemicals & Petrochemicals

Neogen Chemicals Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,034P/E: 169.0Market Cap: ₹4.5K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→FY27 and FY28 are expected to see double-digit revenue growth in the base business, especially post the Dahej plant ramp-up.
→Battery chemicals segment projected to generate INR 400-500 crore revenue in FY27, considering limited salt sales from Pakhajan in H2 FY27.
→Electrolyte revenues are expected to increase in H2 FY27 due to capacity ramps by major customers like Ola, Exide, and Waaree.
→The Pakhajan salt plant’s full 30,000 MT capacity is targeted to be operational by end of H1 FY27, with gradual ramp-up based on business visibility.
→By end of 2027, India's battery cell manufacturing capacity expected to reach 40-50 GWh with new and expanding capacities.
→Salt capacity currently sufficient till FY28; potential need for capacity addition by FY29 depending on international and local demand.
→The Dahej replacement plant commissioning is on track for Q1 FY27, supporting growth ambitions and future sales expansion.

Margin guidance

Category 3

→Neogen Chemicals expects steady revenue growth driven by the ramp-up of battery chemicals, including electrolyte and salts production at the Dahej and Pakhajan plants.
→FY27 battery chemicals revenue is guided at INR 400-500 crore with electrolyte production from Pakhajan starting in H1 FY27 and salts in H2.
→Base business (organic and inorganic chemicals) is expected to deliver double-digit revenue growth in FY27 and FY28, recovering from fire incident impacts.
→EBITDA impacted short-term by ramp-up costs, interim toll manufacturing, and higher interest expense related to Dahej plant reconstruction but expected to improve with insurance claim recoveries and operating efficiencies.
→Promoter equity infusion of INR 150 crore and $20 million from Morita aid in reducing interest burden and support growth initiatives.
→Full capacity utilization at Dahej (30,000 MT salt) targeted by end H1 FY27 with gradual ramp-up aligned with demand visibility.
→Insurance claims will partially offset transient costs in FY27 and FY28, supporting profit recovery.
→Overall, management is confident about growth, margin expansion, and long-term value creation as projects come online.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Promoter group plans a preferential equity infusion of INR 150 crore, expected before March 2026 or by Q1 FY27, subject to regulatory approvals.
→Around INR 200 crore equity expected from Morita towards their 20% stake in the JV by end of current quarter or Q1 FY27.
→Insurance claim recoveries of approximately INR 200 crore expected by March or April 2026.
→Overall, approximately INR 550 crore (equity + insurance) expected to come in this year or early next year.
→Debt discussions ongoing with banks to maintain a 70:30 debt-equity ratio for the JV capital; exact debt levels and repayments are being finalized.
→First principal repayment for Dahej loans expected in Q1 FY28, about one year after SCOD.
→Some of the funds raised will be used for working capital and capex contributions for ongoing projects.

Order book

→Salt business has shown increased interest with many regular and non-regular customers.
→Majority of requirements for one key customer are complete, with final approval timelines expected by Q1 FY27.
→Three to four other customers have started sampling and approving, with audits planned between March and May 2026.
→Dahej site approval expected by June 2026; sales to start progressively from Q2 FY27 onwards.
→Pakhajan site target approval by September 2026, with trial production starting in H2 FY27 and sales from Q4 FY27.
→Significant inquiries for lithium salts and intermediates due to regulatory changes and demand growth.
→Provisional approvals received from multiple global clients with final audits completing in Q1 FY27.
→Overall, order book and pending approvals are progressing well, enabling ramp-up of supply capacity through 2026 and beyond.

Capex plans

Yes

→Neogen Chemicals is progressing with the Pakhajan greenfield project, targeting:
→ - Electrolyte commercial production in H1 FY27.
→ - Electrolyte salts production in H2 FY27.
→ - Equipment arrival and assembly underway; trial production expected soon.
→Rebuilding and expansion of the Dahej plant ongoing, with completion and commissioning expected by Q1 FY27 and capacity ramp-up by March 2026.
→Preferential equity infusion planned from Promoter Group of INR 150 crore by March 2026 to support growth and reduce interest burden.
→Joint venture with Morita Investment Ltd for LiPF6 salt production, with $20 million investment for 20% stake, expected receipt by Q1 FY27.
→Planned capacity includes readiness for 30,000 MT salt production and 30 gigawatt-hours electrolyte production by end of H1 FY27.
→Potential future capacity additions considered around FY29 based on demand growth, with decisions expected by end of FY27/FY28.

How does Neogen Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Neogen Chemicals Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Neogen Chemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio